Market revenue in 2023 | USD 586.3 million |
Market revenue in 2030 | USD 1,144.4 million |
Growth rate | 10% (CAGR from 2023 to 2030) |
Largest segment | Circulating cell free dna (ccfdna) |
Fastest growing segment | Circulating Cell Free DNA (ccfDNA) |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Circulating Cell Free DNA (ccfDNA) |
Key market players worldwide | Qiagen NV, Charles River Laboratories International Inc, Roche Holding AG ADR, Thermo Fisher Scientific Inc, Eurofins Scientific SE, PerkinElmer, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Merck KGaA, Siemens Healthineers AG ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare biomarkers specimen collection and stabilization market will help companies and investors design strategic landscapes.
Circulating cell free dna (ccfdna) was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Middle East & Africa rare biomarkers specimen collection and stabilization market based on circulating cell free dna (ccfdna) covering the revenue growth of each sub-segment from 2018 to 2030.
Presence of distribution network of global cancer diagnostic companies in the region is driving the regional revenue. For instance, in July 2018, Biocept signed an agreement with Alliance Global FZ for marketing and distribution of Biocept’s Target Selector liquid biopsy tests in the UAE and some countries in the North & sub-Saharan Africa, Middle East, and Southeast Asia.
In addition, expanding landscape of genetic testing in this region is anticipated to drive the adoption of biomarker isolation solutions in the region. Genetic tests are performed in countries like UAE as population screening programs to assess if the population has a pre-disposition toward noncommunicable diseases.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa rare biomarkers specimen collection and stabilization market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa rare biomarkers specimen collection and stabilization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account